BenevolentAI (The Benevolent Platform™)

Ingest 20+ years of ALS literature into the Knowledge Graph.

Apply Graph Neural Networks to identify peripheral gene nodes.

Filter for targets with high 'druggability' scores.

Validate in-silico using patient-derived transcriptomics.

Map disease signature against drug-mechanism database.

Simulate drug-target interactions via molecular docking.

Predict efficacy using animal model proxy data.

Generate clinical trial protocol for repurposed candidate.

Input parent molecule into Generative Design suite.

Set multi-objective optimization for high potency and low liver toxicity.

Review 10,000 AI-generated analogs.

Select top 5 for synthesis and wet-lab testing.

Cluster patient data using multi-omics profiles.

Identify specific biomarkers correlating with drug response.

Develop a companion diagnostic framework.

Enroll stratified cohorts in Phase II trials.

Run molecular fingerprints through the deep-tox models.

Analyze potential off-target binding in the Knowledge Graph.

Score cardiotoxicity risks early.

Modify chemical structure to avoid identified toxicophores.

Analyze longitudinal proteomic data from trial participants.

Use AI to identify protein clusters that precede symptom flares.

Cross-validate with genetic risk scores.

Define new surrogate endpoints for clinical efficacy.

Parallelize AI design with automated synthesis labs.

Use active learning to pick the next best experiment.

Reduce physical iterations through high-fidelity simulations.

Deliver lead candidate in under 6 months.